Phosphorus binder composition for treatment of hyperphosphatemia
AssigneeBioLink Life Sciences, Inc.
InventorDeanna J. Nelson
Life of this patent
Estimating the term…
Abstract
The present invention relates to oral pharmaceutical products which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy.
Claims2
A composition for inhibiting absorption of phosphorus-containing anions from the gastrointestinal tract of a subject consisting of:
- a source of ionized calcium, a stool softener, and a non-gelatin capsule, wherein:
- a) the source of ionized calcium is a calcium succinate composition,
- b) the quantity of the calcium succinate composition provides ionized calcium in a quantity sufficient to bind with said phosphorus-containing anions in the gastrointestinal tract of the subject,
- c) the quantity of said stool softener is sufficient to reduce the incidence of constipation but not sufficient to increase the incidence of diarrhea,
- d) said stool softener is selected from the group consisting of docusate and lactulose,
- e) said stool softener does not interfere with the binding of said phosphorus-containing anions by said ionized calcium,
- f) said stool softener does not interfere with the manufacture of said composition,
- g) dissolution of the composition in water at 37° C. that is stirred at 50 RPM under the dissolution conditions described in the U.S. Pharmacopeia for Apparatus II releases at least about 80% of the calcium in the composition as ionized calcium in 30 minutes.
Dependencies are inferred from the claim text.